The trial design is currently being discussed with the FDA, with trial commencement expected to begin by the end of 2005.
“We are very pleased to be selected by Biomira to work on this important program,” said PRA International president and CEO Patrick Donnelly. “We look forward to utilizing our significant global experience and expertise in oncology to deliver the Project Assurance Difference to Biomira.”
Biomira Inc is a biotechnology company applying its technology in immunotherapy and organic chemistry to the development of cancer therapeutics. The company is currently focused on synthetic therapeutic vaccines and innovative strategies for the stimulation of the immune system in the treatment of cancer.